In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Sorana Caterina AntonFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Alin Horatiu NedelcuFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-0024-0237 Victor IanoleFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-2191-6697 Carmen AntonFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0001-7717-1738 Mihai DanciuFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-0194-7832 Ionela Daniela MorariuFaculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-7083-8197 Ancuța LupuFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0001-8147-3632 Gabriel DascalescuDepartment of Biology, Faculty of Biology, Alexandru Ioan Cuza University of Iasi, B-Dul Carol I, No. 11, 700506 Iasi, Romania.ORCID 0009-0001-1962-7861 Vasile Valeriu LupuFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0003-2640-8795 Anton KnielingFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Delia NicolaiciucFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Alin CiobicaDepartment of Biology, Faculty of Biology, Alexandru Ioan Cuza University of Iasi, B-Dul Carol I, No. 11, 700506 Iasi, Romania.
Elena Andreea ChivasutaFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Mihaela TirnovanuFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Iurie DondiucDepartment of Obstetrics and Gynecology, "Nicolae Testemitanu" University of Medicine and Pharmacy, 2004 Chisinau, Moldova.
Ciprian IleaFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Mihaela GrigoreFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-6530-6874 Emil AntonFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-8244-0522 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Aggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC) and tumors in BRCA1 germline mutation carriers, present significant clinical challenges. The role of BRCA1 protein expression, assessed via immunohistochemistry (IHC), in defining the biology of these high-risk tumors remains to be fully elucidated. We performed a semi-quantitative IHC analysis of BRCA1 protein expression in a targeted cohort of 100 invasive breast carcinomas, enriched for TNBC (88%) and BRCA1 mutation carriers (34%). A validated monoclonal antibody and a composite scoring system (0-9) were employed, with an optimal cut-off defined by ROC analysis. Associations with clinicopathological parameters and p16 expression were evaluated. Low BRCA1 expression was strongly associated with an aggressive phenotype, including invasive ductal histology, hormone receptor negativity, and the TNBC subtype (all
Indexed as
BRCA1 ProteinBreast NeoplasmsTriple Negative Breast NeoplasmsAdultBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16FemaleGerm-Line MutationHumansImmunohistochemistryMiddle AgedTumor MicroenvironmentBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanCyclin-Dependent Kinase Inhibitor p16biomarkerBRCA1immunohistochemistrytriple-negative breast cancertumor microenvironment
Identifiers
PMID41751865
PMCPMC12940674
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390